Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Active, not recruiting
• Trial end date: 2023-05-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the intraocular pressure-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Diagnosis of either Open-Angle Glaucoma or Ocular Hypertension in each eye that require IOP lowering treatment.

Exclusion Criteria:

• Eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months.

• Previous use of commercially available Bimatoprost SR; c oncurrent enrollment in another Allergan Bimatoprost SR study; or previous enrollment in which an implant was received.